JDM  Vol.2 No.2 , May 2012
Four-hour evaluation of a medical food in subjects with type 2 diabetes receiving oral hypoglycemic medication
Abstract: Background: Postprandial hyperglycemia is an independent risk factor for diabetes-associated complications in individuals with type 2 diabetes. Dietary modification plays an important role in glycemic control. This study was to examine the efficacy of a diabetes specific formula (DSF) during a 4-hour postprandial meal tolerance test (MTT) in Russian subjects with type 2 diabetes receiving oral hypoglycemic medication. Methods: In a randomized, cross-over design, 168 eligible subjects from 11 study centers consumed, in a random order, the DSF (230 mL) or a common light hospital breakfast (i.e. standard meal) on two different occasions. The amounts of macronutrients were similar between the two meals providing ~200 kcal, 11 g protein, 26 g carbohydrate and 8 g fat. Capillary glucose levels were measured at baseline (before meal consumption), and post-meal consumption at 30, 60, 90, 120, 180 and 240 min. Results: The DSF was well tolerated in all subjects. There were 111 subjects completed the study per protocol (mean ± SEM: age: 58.6 ± 0.8 yr, BMI: 31.8 ± 0.42 kg/m2, waist circumference: 101 ± 1.3 cm, HbA1c: 8.0% ± 0.1%). Glucose levels reached peak values at 60 min (median) and the lowest levels at the end of the 240-min MTT test. The mean positive area under the curve (PAUC), the primary outcome, was significantly smaller after DSF consumption (mean ± SEM: 183.02 ± 18.74, median: 132.55) than the PAUC after consumption of the standard meal (mean ± SEM: 239.95 ± 23.11, median: 166.89; p = 0.027). The actual and adjusted peak glucose concentrations were similar between the two treatments. Conclusions: In patients with type 2 diabetes receiving oral hypoglycemic agents, compared to a hospital meal, the DSF improves postprandial glucose control. Combining results from earlier studies, long-term use of DSF may be beneficial to improve glucose management and decrease diabetes-associated complications.
Cite this paper: Luo, M. , C. Voss, A. , A. Mustad, V. , Ivanova, L. , Morugova, T. , Alexeeva, E. , Ruyatkina, L. and Suplotova, L. (2012) Four-hour evaluation of a medical food in subjects with type 2 diabetes receiving oral hypoglycemic medication. Journal of Diabetes Mellitus, 2, 214-220. doi: 10.4236/jdm.2012.22034.

[1]   Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-1053. doi:10.2337/diacare.27.5.1047

[2]   Diabetes Atlas. (2009) International Diabetes Federation.

[3]   The Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329, 977-986. doi:10.1056/NEJM199309303291401

[4]   UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352, 837-853. doi:10.1016/S0140-6736(98)07019-6

[5]   Ceriello, A. and Colagiuri, S. (2008) International Diabetes Federation guideline for management of postmeal glucose: A review of recommendations. Diabetes Medicine, 25, 1151-1156. doi:10.1111/j.1464-5491.2008.02565.x

[6]   Woerle, H.J., Neumann, C., Zschau, S., Tenner, S., Irsigler, A., Schirra, J., et al. (2007) Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Research Clinical Practice, 77, 280-285. doi:10.1016/j.diabres.2006.11.011

[7]   Pastors, J.G., Warshaw, H., Daly, A., Franz, M. and Kulkarni, K. (2002) The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care, 25, 608-613. doi:10.2337/diacare.25.3.608

[8]   Sun, J., Wang, Y., Chen, X., Chen, Y., Feng, Y., Zhang, X., et al. (2008) An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. Asia Pacific Journal of Clinical Nutrition, 17, 514-524.

[9]   Climt, C.R., Prout, T.E., Bradley, R.F., Dolger, H., Fisher, G., Gastineau, C.F., et al. (1969) Standardization of the oral glucose tolerance test. Diabetes, 18, 299-307.

[10]   Wolever, T.M., Jenkins, D.J., Jenkins, A.L. and Josse, R.G. (1991) The glycemic index: Methodology and clinical implications. American Journal of Clinical Nutrition, 54, 846-854.

[11]   Via, M.A. and Mechanick, J.I. (2011) Inpatient enteral and parenteral (corrected) nutrition for patients with diabetes. Current Diabetes Reports, 11, 99-105. doi:10.1007/s11892-010-0168-5

[12]   Gonzalez-Ortiz, M., Martinez-Abundis, E., Hernandez-Salazar, E., Kam-Ramos, A.M. and Robles-Cervantes, J.A. (2006) Effect of a nutritional liquid supplement designed for the patient with diabetes mellitus (Glucerna SR) on the postprandial glucose state, insulin secretion and insulin sensitivity in healthy subjects. Diabetes Obesity Metabolism, 8, 331-335. doi:10.1111/j.1463-1326.2005.00512.x

[13]   Coulston, A.M. (1998) Clinical experience with modified enteral formulas for patients with diabetes. Clinical Nutrition, 17, 46-56. doi:10.1016/S0261-5614(98)80017-4

[14]   McCargar, L.J., Innis, S.M., Bowron, E., Leichter, J., Dawson, K., Toth, E. and Wall, K. (1998) Effect of enteral nutritional products differing in carbohydrate and fat on indices of carbohydrate and lipid metabolism in patients with NIDDM. Molecular Cellular Biochemistry, 188, 81-89. doi:10.1023/A:1006872506658

[15]   Bantle, J.P., Wylie-Rosett, J., Albright, A.L., Apovian, C.M., Clark, N.G., Franz, M.J., et al. (2008) Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care, 31, S61-S78. doi:10.2337/dc08-S061

[16]   Boj-Carceller, D., Bocos-Terraz, P., Moreno-Vernis, M., Sanz-Paris, A., Trincado-Aznar, P. and Albero-Gamboa, R. (2011) Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World Journal of Diabetes, 2, 217-220. doi:10.4239/wjd.v2.i12.217

[17]   Monnier, L. and Colette, C. (2006) Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocrine Practice, 12, 42-46.

[18]   Stolar, M. (2010) Glycemic control and complications in type 2 diabetes mellitus. American Journal of Medicine, 123, S3-S11. doi:10.1016/j.amjmed.2009.12.004

[19]   Nuttall, F.Q., Gannon, M.C., Burmeister, L.A., Lane, J.T. and Pyzdrowski, K.L. (1992) The metabolic response to various doses of fructose in type II diabetic subjects. Metabolism, 41, 510-517. doi:10.1016/0026-0495(92)90210-2

[20]   Wolf, B.W., Humphrey, P.M., Hadley, C.W., Maharry, K.S., Garleb, K.A. and Firkins, J.L. (2002) Supplemental fructose attenuates postprandial glycemia in Zucker fatty fa/fa rats. Journal of Nutrition, 132, 1219-1223.

[21]   Wakabayashi, S., Kishimoto, Y. and Matsuoka, A. (1995) Effects of indigestible dextrin on glucose tolerance in rats. Journal of Endocrinology, 144, 533-538. doi:10.1677/joe.0.1440533

[22]   Lichtenstein, A.H., Appel, L.J., Brands, M., Carnethon, M., Daniels, S., Franch, H.A., et al. (2006) Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation, 114, 82-96. doi:10.1161/CIRCULATIONAHA.106.176158

[23]   Sanz-Paris, A., Calvo, L., Guallard, A., Salazar, I. and Albero, R. (1998) High-fat versus high-carbohydrate enteral formulae: Effect on blood glucose, C-peptide, and ketones in patients with type 2 diabetes treated with insulin or sulfonylurea. Nutrition, 14, 840-845. doi:10.1016/S0899-9007(98)00124-5

[24]   West, S.G., Hecker, K.D., Mustad, V.A., Nicholson, S., Schoemer, S.L., Wagner, P., Hinderliter, A.L., Ulbrecht, J., Ruey, P. and Kris-Etherton, P.M. (2005) Acute effects of monounsaturated fatty acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. Diabetologia, 48, 113-122. doi:10.1007/s00125-004-1600-7